Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28461176 | 0.97 | LMNA (0.42) | LMNAMEN1CYP2D6HRH1SCN1A | |
| SCHEMBL15667904 | 0.84 | — | — | |
| SCHEMBL15667935 | 0.84 | — | — | |
| SCHEMBL2485059 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL25315391 | 0.82 | LMNA (0.35) | LMNAMEN1CYP2D6HRH1SCN1A | |
| Hydrochloric Acid SCHEMBL571900 | 0.82 | LMNA (0.35) | LMNAMEN1CYP2D6HRH1SCN1A | |
| Hydrochloric Acid SCHEMBL30218279 | 0.82 | LMNA (0.35) | LMNAMEN1CYP2D6HRH1SCN1A | |
| Hydrochloric Acid SCHEMBL16600271 | 0.82 | LMNA (0.35) | LMNAMEN1CYP2D6HRH1SCN1A | |
| SCHEMBL14246961 | 0.81 | LMNA (0.42) | LMNAMEN1CYP2D6HRH1SCN1A | |
| SCHEMBL27925056 | 0.81 | LMNA (0.42) | LMNAMEN1CYP2D6HRH1SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 676 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111606842-A | Preparation method of 2- (4-piperidyl) -2-propanol and hydrochloride thereof | 安徽中羰碳一工业技术有限责任公司 | 2020-09-01 | — | — | CN | claimed |
| CN-106366093-B | Fused ring pyrimidine compound, intermediate, preparation method, composition and application thereof | 广州再极医药科技有限公司 | 2020-08-18 | — | — | CN | claimed |
| US-10494378-B2 | Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2019-12-03 | — | — | US | claimed |
| EP-3354653-B1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD (CN) | 2019-09-04 | — | — | EP | claimed |
| EP-3354653-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | Guangzhou Maxinovel Pharmaceuticals Co. Ltd. (CN) | 2018-08-01 | — | — | EP | claimed |
| US-20180208604-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2018-07-26 | — | — | US | claimed |
| CN-106366093-A | Fused pyrimidine compound, and intermediate, preparation method, composition and application of | 广州再极医药科技有限公司 | 2017-02-01 | — | — | CN | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026100508-A1 | RESIN COMPOSITION, CURED PRODUCT, LAMINATE, METHOD FOR PRODUCING CURED PRODUCT, METHOD FOR PRODUCING LAMINATE, METHOD FOR PRODUCING SEMICONDUCTOR DEVICE, SEMICONDUCTOR DEVICE, AND RESIN | 富士フイルム株式会社 | 2026-05-15 | — | — | WO | disclosed |
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4737451-A1 | NOVEL CARBOXAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2026-05-06 | — | — | EP | disclosed |
| US-20260099093-A1 | PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR PRODUCING CURED RELIEF PATTERN USING SAME, AND METHOD FOR PRODUCING POLYIMIDE FILM USING SAME | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2026-04-09 | — | — | US | disclosed |
| EP-4722211-A1 | FGFR2/3 SELECTIVE INHIBITOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| EP-1456200-A1 | LACTAMS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003051868-A1 | LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 2003-06-26 | — | — | WO | disclosed |
| EP-0625509-B1 | N-alkyl substituted piperidine-derivatives with neurokinin receptor antagonist activity | ZENECA LTD (GB) | 1997-07-30 | — | — | EP | disclosed |
| US-5521199-A | TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0625509-A1 | N-alkyl substituted piperidine-derivatives with neurokinin receptor antagonist activity | ZENECA LIMITED (GB) | 1994-11-23 | — | — | EP | disclosed |
| CN-1017435-B | PROCESS FOR PREPARATION OF GLYCEROL DERIVATIVES | NIPPON CHEMIPHAR CO (JP) | 1992-07-15 | — | — | CN | disclosed |
| CN-1030239-A | The preparation method of new glycerol derivative | NIPPON CHEMIPHAR CO (JP) | 1989-01-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260099093-A1 | PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR PRODUCING CURED RELIEF PATTERN USING SAME, AND METHOD FOR PRODUCING POLYIMIDE FILM USING SAME | CD79B, ITGA1, PTK2 | LMNA 3565/4885MEN1 2775/4885CYP2D6 4544/4885 |
| US-20180208604-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | FLT3, FGFR1, FGFR3 | LMNA 4690/4885MEN1 3448/4885CYP2D6 843/4885 |
| US-10494378-B2 | Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof | FLT3, FGFR1, FGFR3 | LMNA 4690/4885MEN1 3448/4885CYP2D6 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.